肠溶空胶囊市场机会、成长动力、产业趋势分析及2025-2034年预测

2024年，全球肠溶空胶囊市场规模达27亿美元，预计到2034年将以6.9%的复合年增长率成长，达到52亿美元。推动这一增长的动力源于对先进药物输送系统日益增长的需求，这些系统能够确保活性药物和营养成分的靶向缓释。肠溶胶囊能够保护敏感成分免受胃酸侵蚀，并将其直接输送至肠道，因此对胃肠道药物和酸敏疗法至关重要。肠溶胶囊用途广泛，涵盖抗生素、抗酸剂和酵素製剂，是现代製剂的重要组成部分。

个人化医疗和以患者为中心的设计模式的快速发展，得益于其配方灵活性以及与多种活性成分的兼容性，进一步推动了市场需求。在日益壮大的营养保健领域，肠溶胶囊（尤其是以羟丙基甲基纤维素 (HPMC) 为基础的纯素食型肠溶胶囊）越来越受到益生菌、酵素和草药补充剂的青睐。人们对清洁标籤和植物性产品的青睐，促使製造商投资于无硅酮的素食胶囊替代品。

2024年，明胶市场规模达16亿美元。其价格实惠、成膜性好、易于生产，使其成为大规模胶囊生产的预设选择，尤其是在非素食配方的领域。其监管便利性以及与多种API的兼容性，使其成为众多製药和补充剂生产商的首选。

肠溶空胶囊应用于抗生素和抗菌药物领域，2024年该领域市占率为43.5%。这些胶囊可以保护对酸敏感的抗生素免于胃降解，确保其在肠道中达到最佳吸收效果。它们还有助于最大限度地减少副作用，并掩盖某些药物的不良味道，从而提高患者的依从性和治疗成功率。

2024年，美国肠溶空胶囊市场规模达9.868亿美元，这得益于数千万人普遍患有的胃肠道疾病，以及成年人补充剂摄取量的强劲增长。美国食品药物管理局（FDA）和美国农业部（USDA）等机构的监管明确性，支持pH依赖型和缓释胶囊技术的快速开发和应用。

该行业的主要製造商包括龙沙集团 (Lonza)、罗盖特集团 (Roquette Freres)、Chemcaps、光明製药 (Bright Pharma Caps)、青岛一清 (Qingdao Yiqing)、ACG Worldwide、天然胶囊 (Natural Capsules)、益阳製药 (Yiyaa Pharma)、Capsm、Fortm） Healthcare、CapsCanada、Suheung 和浙江汇利胶囊 (Zhezhou Huili Capsules)。为了巩固市场地位，肠溶空心胶囊领域的领先製造商正在部署多项关键策略。他们正在投资研发创新胶囊材料，例如羟丙基甲基纤维素 (HPMC) 和植物性聚合物，以吸引註重健康的消费者并符合监管标准。

与製药和营养保健品公司建立策略合作伙伴关係，有助于共同开发针对特定 API 和递送系统的客製化解决方案。许多公司正在扩大产能，并在更靠近区域枢纽的地方建立生产设施，以提高供应链效率。专注于清洁标籤、纯素认证和透明的生产流程，以满足消费者对符合道德和安全产品的需求。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
  • 供应商格局
  • 每个阶段的增值
  • 影响价值链的因素
• 产业衝击力
  • 成长动力
    • 靶向药物传输需求不断增长
    • 素食胶囊替代品日益受到青睐
    • 个性化医疗解决方案的扩展
    • 胶囊包衣技术的进步
  • 产业陷阱与挑战
    • 肠溶製剂的监管复杂性
    • 生产和涂层成本高
  • 市场机会
    • 全球营养保健品消费量不断成长
    • 发展中经济体对非处方药和补充剂的需求不断增加
• 成长潜力分析
• 未来市场趋势
• 消费者行为分析
• 监管格局
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展
  • 併购
  • 伙伴关係与协作
  • 新产品发布
  • 扩张计划

第五章：市场估计与预测：按产品，2021 - 2034 年

• 主要趋势
• 明胶胶囊
• 非明胶胶囊
  • HPMC（羟丙基甲基纤维素）
  • 普鲁兰多醣胶囊
  • 淀粉基胶囊
  • 其他非明胶胶囊

第六章：市场估计与预测：按应用，2021 - 2034 年

• 主要趋势
• 抗酸剂和抗胀气剂
• 抗生素和抗菌药物
• 其他应用

第七章：市场估计与预测：按胶囊尺寸，2021 - 2034 年

• 主要趋势
• 00号
• 0号尺寸
• 尺寸 1
• 其他胶囊尺寸

第八章：市场估计与预测：依最终用途，2021 - 2034 年

• 主要趋势
• 製药公司
• 营养保健品製造商
• 其他最终用途

第九章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• ACG Worldwide
• Bright Pharma Caps
• CapsCanada
• Capsuline
• Chemcaps
• Fortcaps Healthcare
• Lonza
• Natural Capsules
• Qingdao Yiqing
• Roquette Freres
• Shaoxing Zhongya Capsule
• Suheung
• Yiyang Pharma
• Zhejiang Huili Capsules

The Global Enteric Empty Capsules Market was valued at USD 2.7 billion in 2024 and is estimated to grow at a CAGR of 6.9% to reach USD 5.2 billion by 2034. This surge is being driven by the increasing need for advanced drug delivery systems that ensure targeted, delayed release of active pharmaceutical and nutraceutical compounds. By shielding sensitive ingredients from stomach acidity and delivering them directly to the intestines, enteric capsules are critical for gastrointestinal medications and acid-sensitive therapies. Their versatility extends to antibiotics, antacids, and enzyme treatments, making them an essential component of modern formulations.

The rapid growth of personalized medicine and patient-centric design is further boosting demand, thanks to formulation flexibility and compatibility with diverse active ingredients. In the expanding nutraceutical arena, enteric capsules-especially HPMC-based, vegan-friendly types-are increasingly favored for probiotic, enzyme, and herbal supplement delivery. The preference for clean-label, plant-based options is prompting manufacturers to invest in silicone-free, vegetarian capsule alternatives.

The Gelatin segment generated USD 1.6 billion in 2024. Its affordability, film-forming quality, and ease of production make it the default choice for large-scale capsule manufacturing, especially where non-vegetarian formulations are acceptable. Its regulatory convenience and compatibility with a variety of APIs make it a top choice for many pharmaceutical and supplement producers.

Enteric empty capsules are employed in the antibiotic and antibacterial drugs segment, which held a 43.5% share in 2024. These capsules protect acid-sensitive antibiotics from gastric degradation, ensuring optimal absorption in the intestines. They also help minimize side effects and mask the unpleasant taste of certain medications, improving patient adherence and treatment success.

U.S. Enteric Empty Capsules Market accounted for USD 986.8 million in 2024, driven by widespread gastrointestinal conditions affecting tens of millions of people, and a robust supplement intake among adults. Regulatory clarity from agencies like the FDA and USDA supports fast-track development and adoption of pH-dependent and delayed-release capsule technologies.

Key manufacturers in this industry include Lonza, Roquette Freres, Chemcaps, Bright Pharma Caps, Qingdao Yiqing, ACG Worldwide, Natural Capsules, Yiyang Pharma, Capsuline, Shaoxing Zhongya Capsule, Fortcaps Healthcare, CapsCanada, Suheung, and Zhejiang Huili Capsules. To bolster their market position, leading manufacturers in the enteric empty capsules space are deploying several key strategies. They're investing in R&D to develop innovative capsule materials-such as HPMC and plant-based polymers-that appeal to health-conscious consumers and meet regulatory standards.

Strategic partnerships with pharmaceutical and nutraceutical firms facilitate the co-development of customized solutions tailored to specific APIs and delivery systems. Many companies are expanding production capacities and establishing facilities closer to regional hubs to improve supply chain efficiency. Emphasis on clean-label, vegan-friendly certification, and transparent manufacturing processes addresses consumer demand for ethical and safe products.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumption and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Product
  • 2.2.3 Application
  • 2.2.4 Capsule size
  • 2.2.5 End use
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing demand for targeted drug delivery
    • 3.2.1.2 Growing shift toward vegetarian capsule alternatives
    • 3.2.1.3 Expansion of personalized medicine solutions
    • 3.2.1.4 Advancements in capsule coating technologies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Regulatory complexity for enteric formulations
    • 3.2.2.2 High production and coating costs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing consumption of nutraceutical globally
    • 3.2.3.2 Increasing demand for over-the-counter medications and supplements in developing economies
• 3.3 Growth potential analysis
• 3.4 Future market trends
• 3.5 Consumer behaviour analysis
• 3.6 Regulatory landscape
  • 3.6.1 North America
  • 3.6.2 Europe
  • 3.6.3 Asia Pacific
  • 3.6.4 Latin America
  • 3.6.5 Middle East and Africa
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Gelatin capsules
• 5.3 Non-gelatin capsules
  • 5.3.1 HPMC (hydroxypropyl methylcellulose)
  • 5.3.2 Pullulan capsules
  • 5.3.3 Starch-based capsules
  • 5.3.4 Other non-gelatin capsules

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Antacid and antiflatulent preparations
• 6.3 Antibiotic and antibacterial drugs
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By Capsule Size, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Size 00
• 7.3 Size 0
• 7.4 Size 1
• 7.5 Other capsule size

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Pharmaceutical companies
• 8.3 Nutraceutical manufacturers
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 ACG Worldwide
• 10.2 Bright Pharma Caps
• 10.3 CapsCanada
• 10.4 Capsuline
• 10.5 Chemcaps
• 10.6 Fortcaps Healthcare
• 10.7 Lonza
• 10.8 Natural Capsules
• 10.9 Qingdao Yiqing
• 10.10 Roquette Freres
• 10.11 Shaoxing Zhongya Capsule
• 10.12 Suheung
• 10.13 Yiyang Pharma
• 10.14 Zhejiang Huili Capsules